metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population
versus atezolizumab plus carboplatin plus nab-paclitaxel
	atezolizumab plus carboplatin plus nab-paclitaxel vs. atezolizumab plus carboplatin plus nab-paclitaxel	1	0.80 [0.65; 0.99], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.65 [0.54; 0.78], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
versus bevacizumab plus carboplatin and paclitaxel
	atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel	1	0.76 [0.63; 0.92], 1 RCT, I2=0% unassessable degree of certainty	0.61 [0.52; 0.72], 1 RCT, I2=0% unassessable degree of certainty	-
	atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel	1	0.85 [0.71; 1.02], 1 RCT, I2=0% inconclusive result	0.91 [0.78; 1.06], 1 RCT, I2=0% inconclusive result	-